Biodexa Pharmaceuticals PLC Announces It Appealed The Staff Determination From The Listing Qualifications Department Of The Nasdaq Stock Market LLC
Portfolio Pulse from Happy Mohamed
Biodexa Pharmaceuticals (NASDAQ:BDRX) has appealed the Staff Determination from the Nasdaq Listing Qualifications Department to delist its securities due to closing bid prices below $0.10 for ten consecutive trading days and failure to meet the Minimum Bid Price Rule. The company has until July 31, 2023, to regain compliance.
June 20, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biodexa Pharmaceuticals is appealing Nasdaq's delisting determination due to low closing bid prices and failure to meet the Minimum Bid Price Rule, with a deadline of July 31, 2023, to regain compliance.
Biodexa Pharmaceuticals is facing delisting from Nasdaq due to its failure to meet the Minimum Bid Price Rule and having closing bid prices below $0.10 for ten consecutive trading days. This news is likely to negatively impact the stock price in the short term as investors may be concerned about the company's ability to regain compliance and avoid delisting.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100